Doctorado en Ciencias e Innovación en Medicina, Facultad de Medicina Clínica Alemana Universidad del Desarrollo, Santiago 8320000, Chile.
Servicio de Cirugía Cardiovascular, Instituto Nacional del Tórax, Santiago 7500808, Chile.
Genes (Basel). 2022 Jun 8;13(6):1027. doi: 10.3390/genes13061027.
Marfan Syndrome (MFS) is an autosomal dominant condition caused by variants in the fibrillin-1 () gene. Cardinal features of MFS include ectopia lentis (EL), musculoskeletal features and aortic root aneurysm and dissection. Although dissection of the ascending aorta is the main cause of mortality in MFS, the clinical course differs considerably in age of onset and severity, even among individuals who share the same causative variant, suggesting the existence of additional genetic variants that modify the severity of the cardiovascular phenotype in MFS. We recruited MFS patients and classified them into severe ( = 8) or mild aortic phenotype ( = 14) according to age of presentation of the first aorta-related incident. We used Exome Sequencing to identify the genetic variants associated with the severity of aortic manifestations and we performed linkage analysis where suitable. We found five genes associated with severe aortic phenotype and three genes that could be protective for this phenotype in MFS. These genes regulate components of the extracellular matrix, TGFβ pathway and other signaling pathways that are involved in the maintenance of the ECM or angiogenesis. Further studies will be required to understand the functional effect of these variants and explore novel, personalized risk management and, potentially, therapies for these patients.
马凡综合征(MFS)是一种常染色体显性遗传病,由原纤维蛋白 1(FBN1)基因突变引起。MFS 的主要特征包括晶状体异位(EL)、肌肉骨骼特征和主动脉根部瘤和夹层。尽管升主动脉夹层是 MFS 患者死亡的主要原因,但发病年龄和严重程度的临床病程差异很大,即使是携带相同致病变异的个体也是如此,这表明存在其他遗传变异,可修饰 MFS 心血管表型的严重程度。我们招募了 MFS 患者,并根据首次与主动脉相关的事件发生时的年龄将其分为严重(=8)或轻度主动脉表型(=14)。我们使用外显子组测序来确定与主动脉表现严重程度相关的遗传变异,并在合适的情况下进行连锁分析。我们发现了五个与严重主动脉表型相关的基因和三个可能对 MFS 中这种表型有保护作用的基因。这些基因调节细胞外基质的成分、TGFβ 途径和其他参与 ECM 维持或血管生成的信号通路。需要进一步研究这些变异的功能影响,并探索针对这些患者的新的个体化风险管理和潜在治疗方法。